Literature DB >> 1745487

Acute and delayed emesis after cisplatin-based regimen: description and prevention.

C Louvet1, A Lorange, F Letendre, R Beaulieu, H M Pretty, Y Courchesne, J A Neemeh, M Monte, J Latreille.   

Abstract

Lorazepam, dexamethasone and high-dose metoclopramide were given to 54 patients to prevent emesis induced by cisplatin (50-120 mg/m2) on day 1, while prochlorperazine and dexamethasone were administered on days 2 and 3 for control of delayed emesis. Nausea and emesis were recorded from day 1 to day 8. This combination was well tolerated. Prevention on day 1 was complete for 72% of patients and satisfactory (less than or equal to 2 emeses on day 1) in 85%. From days 2 to 8, no emesis, less than or equal to 2 and greater than 2 episodes occurred in 70, 11 and 19%, respectively. Overall control (days 1-8) was complete in 55.5% and satisfactory (less than or equal to 2 emeses on day 1 and/or less than or equal to 2 emeses from days 2 to 8) in 74%. Delayed emesis started on days 2-5. Mean duration was 2.6 days. Delayed nausea or emesis were more frequent when emesis occurred on day 1. Based on data previously reported and on these observations, better ways to prevent delayed events are discussed. Further trials must record systematically delayed side effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1745487     DOI: 10.1159/000226966

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

Review 1.  Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

Authors:  Mark G Kris; Paul J Hesketh; Jorn Herrstedt; Cynthia Rittenberg; Lawrence H Einhorn; Steven Grunberg; Jim Koeller; Ian Olver; Sussanne Borjeson; Enzo Ballatori
Journal:  Support Care Cancer       Date:  2004-11-23       Impact factor: 3.603

2.  Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study.

Authors:  Alessandra Fabi; Mario Barduagni; Salvatore Lauro; Luigi Portalone; Mariella Mauri; Filippo Marinis; Carla Narduzzi; Giuseppe Tonini; Marianna Giampaolo; Umberto Pacetti; Francesca Paoloni; Francesco Cognetti
Journal:  Support Care Cancer       Date:  2003-01-25       Impact factor: 3.603

Review 3.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

Review 4.  Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.

Authors:  A Del Favero; F Roila; M Tonato
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

5.  Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.

Authors:  K Matsui; M Fukuoka; M Takada; Y Kusunoki; T Yana; K Tamura; T Yoshida; K Iida; T Hirashima; H Tsukada; S Ushijima; H Miyawaki; N Masuda
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.